Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections
about
sameAs
In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis cariniiSummary of information on human CYP enzymes: human P450 metabolism data.Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistanceIn vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Use of anti-infective agents during lactation: Part 1--Beta-lactam antibiotics, vancomycin, quinupristin-dalfopristin, and linezolid.Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.Clinical presentations of soft-tissue infections and surgical site infections.Quinupristin/dalfopristin.Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipientsRisk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy.Treatment of bacterial skin and skin structure infections.A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.Update on the appropriate use of linezolid in clinical practiceMultidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis.Clinical experience of quinupristin-dalfopristin for the treatment of antimicrobial-resistant gram-positive infections.Properties of Basil and Lavender Essential Oils Adsorbed on the Surface of Hydroxyapatite.
P2860
Q28361588-20718199-DC42-48C8-B9B6-80D67429B8D3Q32103802-324F5DDB-6A83-4A24-9AA5-447977BBC65AQ34102811-AA1C61E0-BB3C-4D39-A21D-0BAF8D383734Q34110412-F440E9C3-A6B4-48B8-B11C-6C25B8C44F0BQ34129829-3C36BCFE-AF56-4AB8-A2E0-FFF10D2C3CE6Q34303042-2901032F-82D7-40A7-9B38-FC8B3942966CQ34326486-316F174B-F865-4062-AE6D-91D01204F2DDQ34789160-73123B1B-9B8D-450F-88F4-8B5212AD6446Q35047705-9E247EA6-7543-4CB0-B87E-7FC1DCF426FCQ35047852-03848E13-98D6-4FEF-8CDF-125B44575A83Q35066795-33AF89A5-5750-4188-A25B-E000850A60B6Q35183731-958EAA58-5C1A-40AB-A186-DCD7CF076B12Q36170448-5CD19C3C-608C-4EFD-AFD3-5EC5D86F5AFEQ36492132-F97DE4CF-6356-452D-9B37-278E973E7055Q36735202-C46E1C3B-1B18-4E99-85F7-10309D275A2AQ37116859-D1450427-4BB8-456A-BBA4-9DD6A8E6D43CQ38620812-E212D1EA-1383-4353-8030-8B2F8DAD8130Q39792579-B116A5BD-5DC7-4077-9EFE-F65882134725Q40667218-223A7445-B3E9-4AC6-93FF-E43318AD154FQ43636337-0585E9C6-27E5-48A7-9A24-8C5BF092235BQ43999843-8FF8EC3B-7FC7-4D17-9975-46F5774CE28FQ52563287-349D28F6-1B8C-47B5-B063-1CFDDA447650
P2860
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@ast
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@en
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@nl
type
label
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@ast
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@en
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@nl
altLabel
Quinupristin/Dalfopristin
@ast
Quinupristin/Dalfopristin
@en
prefLabel
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@ast
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@en
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@nl
P2093
P1433
P1476
Quinupristin/Dalfopristin
@en
Quinupristin/dalfopristin: a r ...... rious gram-positive infections
@en
P2093
D P Figgitt
Diana Faulds
Harriet M. Lamb
P304
P356
10.2165/00003495-199958060-00008
P407
P577
1999-01-01T00:00:00Z
1999-12-01T00:00:00Z
P6179
1000500057